COVID-19 ENLIST [COVID-19]
Research type
Research Study
Full title
COVID-19 EARLY NOVEL LABORATORY INSIGHT STUDY
IRAS ID
283297
Contact name
Mark James Ponsford
Contact email
Sponsor organisation
Cardiff and Vale University Health Board
Duration of Study in the UK
1 years, 11 months, 27 days
Research summary
COVID-19 is caused by a new coronavirus known as SARS-CoV-2. The majority of people who encounter this virus develop only mild symptoms, however some react severely and require intensive medical support, such as oxygen, anti-viral, and immunosuppressant therapy.
The COVID-19 ENLIST study first aims to make use of samples collected from patients with suspected COVID-19 at presentation to hospital. We will analyze these to identify key features that predict who are at “high risk” of progression to severe disease.
Secondly, we collect samples from patients at regular time points during their admission. This will allow us to track the immune response to the virus. Comparing the pattern of immune responses between treatment responders and non-responders will help identify mechanisms of treatment resistance. This is anticipated to support discovery of new treatments.
The results of the study will be shared to support evidence-based decisions on the response to COVID-19.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
20/YH/0309
Date of REC Opinion
11 Nov 2020
REC opinion
Further Information Favourable Opinion